Compare WST & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WST | RPRX |
|---|---|---|
| Founded | 1923 | 1996 |
| Country | United States | United States |
| Employees | 10800 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.8B | 22.0B |
| IPO Year | 2004 | 2020 |
| Metric | WST | RPRX |
|---|---|---|
| Price | $365.55 | $57.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $325.86 | $51.40 |
| AVG Volume (30 Days) | 674.9K | ★ 3.5M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | 0.30% | ★ 1.90% |
| EPS Growth | ★ 1.49 | N/A |
| EPS | ★ 1.92 | 0.67 |
| Revenue | ★ $2,886,900,000.00 | $2,378,193,000.00 |
| Revenue This Year | $6.76 | $38.63 |
| Revenue Next Year | $6.22 | $4.73 |
| P/E Ratio | $190.59 | ★ $86.22 |
| Revenue Growth | 1.95 | ★ 5.06 |
| 52 Week Low | $206.80 | $34.63 |
| 52 Week High | $367.66 | $57.79 |
| Indicator | WST | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 78.53 | 63.95 |
| Support Level | $253.53 | $38.07 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 7.33 | 1.50 |
| MACD | 2.68 | 0.16 |
| Stochastic Oscillator | 95.80 | 99.55 |
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.